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Biologists are embracing nanotechnology—the engineering and manipulating of entities in 
the 1 to 100 nm range—and are exploiting its potential to develop new therapeutics and 
diagnostics.In late August, behind closed doors 
at the austere National Academy of 
Sciences in Washington D.C., Samuel 
Stupp, a materials scientist and direc-
tor of the Institute for BioNanotech-
nology in Medicine at Northwestern 
University, showed a video clip for 
a committee evaluating the United 
States’ billion-dollar-a-year National 
Nanotechnology Program.
 “Everyone was so quiet watching 
this movie. It was amazing,” recalls 
Clayton Teague, director of the 
National Nanotechnology Coordinat-
ing Office. The video’s protagonist 
was a mouse with a damaged spi-
nal cord that could only barely move 
using its front legs. Stupp’s research 
involves engineering nanomolecules 
called peptide amphiphiles consist-
ing of a hydrocarbon tail attached to a 
peptide into which is inserted amino-
acid sequences that stimulate neu-
rons to seek new connections with 
neighboring neurons. As the video 
clip revealed, two months after the 
injured mouse received an injection of 
Stupp’s peptide amphiphiles, it was 
able to move (albeit awkwardly) using 
all four limbs.
In bench tests, these same 
amphiphiles self-assemble into fibers 
with diameters in the nanometer-scale 
range, and the resulting nanofibers 
form neuron-friendly networks. Ana-
lyzing anatomical, molecular, and 
behavioral results from mice with spi-
nal cord injury, Stupp and his collabo-
rator, Northwestern neurology profes-
sor John A. Kessler, suspect that the 
amphiphiles, which form a gel when 
they self-assemble, prevent scar tis-
sue from forming, thereby allowing 
initiation of the regenerative process 
in the injured spinal cord, a process 
that normally is blocked.Restoring a measure of mobility to 
a paralyzed animal, and the potential 
transfer of such a feat into human 
patients, is just one dramatic trajec-
tory of the maturing and ever better 
funded face of biological nanotech-
nology and its most touted offshoot—
nanomedicine. Its practitioners have 
entered a new era rife with video 
evidence like Stupp’s and Kessler’s, 
patents for sensitive molecular detec-
tors, and nanoparticle-based contrast 
agents for detecting, monitoring, and 
treating many illnesses, from breast 
cancer to cold sores.
Nanotechnology pioneer, Rich-
ard Smalley, won the Nobel Prize in 
Chemistry in 1996 for discovering 
buckyballs—the all-carbon, soccer-
ball-shaped molecules that helped 
to push nanotechnology into high 
gear. Smalley, who died of leukemia 
in October at the age of 62, was one 
of the most vocal champions of the 
beneficial potential of nanotechnol-
ogy, which he argued was destined 
to solve major societal and medical 
problems. In many of his speaking 
engagements since his cancer diag-
nosis in 1999, he asked rhetorically, 
“am I part of the last generation to 
die of cancer, or the first to be saved 
by nanotechnology?” Now there is 
a growing roster of biological nano-
technologists who are taking auda-
cious questions like Smalley’s to heart 
and to their laboratories.
Nano + Technology + Biology
The word “nanotechnology” conjures 
up the notion of human innovation 
and control over objects and proc-
esses on the nanometer scale. This is 
a compelling size range because it is 
here that many technologically useful 
properties emerge from assemblies of Cell 123, Decatoms and molecules. For example, it 
is in this range that semiconductor 
materials, such as cadmium selenide, 
can be designed to emit a rainbow 
of different colors and thereby serve 
as biomarkers in cells. The tools of 
nanotechnology continue to infiltrate 
molecular biology whose objects of 
study—DNA, RNA, and proteins—are 
perhaps the most elegant example of 
nanoscale constructions.
It’s important to avoid confusing 
terms like “nanobiology,” clarifies Jeff 
Schloss, a program director with the 
National Human Genome Research 
Institute and a member of a working 
group that oversees programs within 
the year-old research and develop-
ment framework of the U.S. National 
Cancer Institute (NCI), known as the 
Alliance for Nanotechnology in Can-
cer. After all, Schloss notes, anything 
in biology that is subcellular in size falls 
within the nanometer range. A typi-
cal protein like hemoglobin is about 
5 nm in diameter, DNA’s double helix 
spans about 2 nm, a mitochondrion 
stretches over a few hundred nm. So, 
says Schloss, “if we allow the stuff in 
cells to be considered as nanotech-
nology, then it becomes hopeless to 
separate nanotechnology from regu-
lar biology.” The distinction between 
the two, he says, is that “nanotech-
nology is not nature. Technology is 
something people make.”
Physician Andrew C. von Eschen-
bach, director of the NCI, has repeat-
edly identified nanotechnology as 
central to the Institute’s “Challenge 
Goal” of, in his own words, “eliminat-
ing suffering and death from cancer 
by 2015.” Says Eschenbach: “The 
NCI is engaged in a concerted effort 
to harness the power of nanotechnol-
ogy to radically change the way we ember 16, 2005 ©2005 Elsevier Inc. 967
diagnose, treat, and prevent cancer.”
In 2004, the NCI launched the $144.3 
million, 5-year Alliance for Nanotech-
nology in Cancer. In October of this 
year, the Alliance announced awards 
totaling $26.3 million for the first-year 
funding of seven “centers of cancer 
nanotechnology excellence.” Each of 
these brings together interdisciplinary 
expertise from neighboring academic, 
medical, and corporate partners to 
achieve common goals. Such goals 
include the development of magnetic 
nanoparticles for brain tumor imaging 
and treatment and in vivo nanoscale 
sensing devices that can monitor and 
report on gene expression. The Alli-
ance also announced $7-million worth 
of first-year awards for the establish-
ment of a dozen “Cancer Nanotech-
nology Platform Partnerships,” which 
fund research collaborations focused 
on developing technologies in six pro-
gram areas. These areas include the 
development of in vivo imaging tools 
and methods to assess treatment effi-
cacy in real time.
In addition to the NCI Alliance for 
Nanotechnology in Cancer, the NIH 
has launched a related R&D frame-
work, known as the NIH Nanomedi-
cine Roadmap Initiative, which has 
earmarked about $80 million through 
2009 for medically directed biology 
research on the nanoscale. So far, 
the Alliance has announced awards 
of nearly $6 million, which will fund 
the creation of four Nanomedicine 
Development Centers. Among the 
awardees is the Center for Design of 
Biomimetic Nanoconductors based 
at the University of Illinois, Urbana-
Champaign. There, researchers will 
investigate the basic biology, manipu-
lation, and design of ion channels, 
protein-based pores, and other nano-
scale portals by which ions, chemi-
cal signals, and other molecules can 
move across cell membranes. A pri-
mary goal of the center will be to cull 
ideas from biological systems for the 
design of biobatteries that could be 
useful in implantable devices such as 
artificial retinas.
The European research and devel-
opment community also is gearing up 
for a strategic push into nanomedi-
cine. In September, stakeholders in 968 Cell 123, December 16, 2005 ©2005 industry, private and public research 
centers, and academia released a 
“vision paper” entitled “European 
Technology Platform on NanoM-
edicine: Nanotechnology for Health.” 
According to a spokesman for the 
European Commission’s Research 
Directorate-General’s office, this doc-
ument could lead to the specification 
of nanomedicine as a priority area in 
the European Union’s ongoing Frame-
work Programmes, the latest of which 
encompasses 17.5 billion Euros.
From Bench to Bedside
Even as these large-scale R&D for-
mats are designed and funded, For-
tune 500 companies and startups are 
racing to develop and market biologi-
cal nanotechnologies. Meanwhile, the 
U.S. Food and Drug Administration 
(FDA), the Environmental Protection 
Agency, and other regulatory agen-
cies in the U.S. and abroad struggle 
to identify potential health, environ-
mental, and occupational hazards 
that could come with these new and 
still poorly understood products. 
These same agencies also are work-
ing toward protocols to manage those 
risks. Reports by market analysis 
firms claim that there are more than 
100 nano-based biomedical prod-
ucts—including drugs, drug-delivery 
systems, therapeutic devices, and 
diagnostic tests—in various stages of 
development and commercialization.
In January this year, the FDA 
approved Abraxane—described by 
the NCI “as the first of a new class of 
‘protein-bound particle’ drugs”—for 
treating metastatic breast cancer 
patients who do not respond to chem-
otherapy or whose cancer returns 
after such treatment. Developed by 
American Pharmaceutical Partners 
in Schaumburg, Illinois and Santa 
Monica-based American Bioscience, 
Abraxane consists of molecules of the 
chemotherapy agent taxol (paclitaxel) 
attached to the blood serum protein 
albumin to form injectable medicinal 
nanoparticles. Phase III clinical trials 
in 454 breast cancer patients showed 
that Abraxane was better than Taxol 
alone at reducing the size of tumors 
(about 33% reduction for Abraxane 
treatment compared with 19% for Elsevier Inc.Taxol alone) and at slowing tumor 
progression (about 22 weeks with no 
worsening of breast cancer for Abrax-
ane compared with about 16 weeks 
for Taxol). In the standard Taxol 
treatment, the active drug (which is 
highly insoluble in water) is dissolved 
in a solvent derived from castor oil 
that can have serious side effects in 
patients. Because of its lower toxicity, 
Abraxane treatment can safely deliver 
more active drug to tumors.
Among other investigational nano-
medicines in clinical testing is Com-
bidex, a magnetic nanoparticle that 
can be used to make certain cancers 
stand out more obviously in magnetic 
resonance imaging scans. These par-
ticles consist of nanoscale clumps of 
iron oxide wrapped in a carbohydrate 
shell, resulting in nanoparticles with 
a diameter of 40 nm. Because these 
nanoparticles are taken up by mac-
rophages (immune cells present in 
healthy lymph nodes but not in can-
cerous nodes), the particles accu-
mulate selectively in noncancerous 
lymph nodes. In MRI scans, therefore, 
healthy lymph nodes produce bigger 
signals, which makes them appear 
dark compared to cancerous nodes, 
which appear lighter. One aim of the 
technique is to help distinguish nodes 
that are enlarged due to cancer from 
those enlarged due to inflammation. 
Made by Advanced Magnetics Inc. in 
Cambridge, Massachusetts, the FDA 
issued this past March a so-called 
“approvable letter,” which indicates 
that the new nanoparticle-based con-
trast agent can be approved as long 
as the company provides additional 
clinical data.
A Biological Nanotechnologist Is 
Born
Abraxane and Combidex represent 
perhaps the largest class of nano-
scale products in various stages 
of development, that is, nanoparti-
cles. By mixing and matching vari-
ous cores—made of polymers, metal 
oxides, semiconductor materials 
like cadmium selenide, and carbon 
nanotubes—with different coatings 
and molecular appendages (that add 
capabilities such as tissue-targeting, 
drug-delivery, imaging enhancement, 
and selective ability to absorb laser 
energy), researchers are developing 
a catalog of nanoparticles for medical 
applications.
One of the more visible players in 
this arena is James Baker, director of 
the Michigan Nanotechnology Institute 
for Medicine and Biological Sciences. 
It was the known dangers of another 
emerging molecular technology in the 
1990s, gene therapy, that prompted 
his entry into the field of nanotech-
nology research. He was dismayed 
by the death in 1999 of 18-year-old 
Jesse Gelsinger during a controversial 
human trial of an experimental gene 
therapy treatment. Baker says, “at that 
point, it struck me that what was really 
needed was synthetic systems” that 
would be less likely to elicit dangerous 
immune responses. For many medical 
applications, he knew the most basic 
structural criterion that such systems 
would have to meet: “You have to be in 
a certain size range to get out of blood 
vessels and into cells—bigger than 25 
nm but smaller than 70 nm,” he says. 
That’s right in the middle of the clas-
sic size range—1 to 100 nm—that 
the nanotechnology community has 
defined as its own.
By the mid-1990s, Baker and a few 
dozen colleagues in a variety of dis-
ciplines began pooling their expertise 
with the goal of developing medically 
valuable nanoparticles whose struc-
tures and properties were sufficiently 
uniform and well characterized to 
meet stringent FDA requirements for 
any drug candidate. In the late 1990s, 
the NCI awarded Baker and his col-
leagues a $12 million grant to, in Bak-
er’s words, “develop a platform that 
essentially would diagnose a cancer, 
treat it, image the tumor, and also see 
if the tumor was responding.” (Baker 
also is the principal investigator for 
one of the Cancer Nanotechnol-
ogy Platform Partnerships recently 
awarded by NCI.)
The nanoparticles that Baker and 
his colleagues are developing as drug 
delivery vehicles are called dendrim-
ers. A dendrimer is an unusually well-
defined polymer structure built up 
using simple monomeric units from 
a central core in precisely control-
led steps that sequentially add lay-ers. This synthetic procedure leads 
to spherical bush-like structures of 
specified and uniform nanoscale 
sizes. Conventional polymers grow 
into linear and often branching struc-
tures, but the individual molecules 
range vastly in size, a nonuniformity 
that would be unlikely to pass muster 
with the FDA.
The most advanced dendrimer 
designed by Baker’s team so far is 
based on a PAMAM (polyamidoam-
ine) dendrimer that contains a mech-
anism for directing the dendrimer to 
cancer cells and a means for deliv-
ering an anticancer drug, such as 
methotrexate, once the nanoparticle 
has reached its target. “Targeting 
drugs directly to cancer cells reduces 
the amount that gets to normal cells, 
increases the drug’s anticancer 
effect, and reduces its toxicity,” Baker 
says. To achieve such targeting, the 
researchers attach molecules of folate 
to chemical “hooks” built into the 
PAMAM nanoparticles. Because cer-
tain types of cancer cells overexpress 
folate receptors, dendrimers bearing 
folate molecules are able to home to 
these cells and stick to them.
First, the investigators showed that 
when folate-bearing PAMAM nanopar-
ticles carrying fluorescent marker mol-
ecules were injected into mice bearing 
certain human tumors the dendrimers 
became sequestered in the cancer-
ous tissue. With up to 120 attachment 
points for molecular appendages, the 
PAMAM dendrimers can be readily 
engineered to carry chemotherapy 
agents such as methotrexate. In the 
June 15 issue of Cancer Research, 
Baker and his collaborators report 
that between 30 and 40 percent of the 
mice receiving the dendrimer-meth-
otrexate nanoparticles lived for the tri-
al’s entire 99 day duration, whereas all 
mice in the control group died in that 
time period. By Baker’s calculations, 
a three month delay in tumor growth 
for a mouse may be equivalent to a 
three year delay in the progression of 
a tumor in human patients.
Proceed with Caution
Their therapeutic potential notwith-
standing, the question arises of 
whether nanoscale particles pose toxi-Cell 123, Deccological dangers that nobody has yet 
anticipated. The small portfolio of toxi-
cology studies in hand so far suggest 
that nanoparticles, such as buckyballs 
and related all-carbon particles known 
as buckytubes, indeed can pose 
respiratory hazards in a similar way 
to nanoscale soot particles in diesel 
exhaust. But the higher-stakes ques-
tion is whether the various nanoscale 
particles researchers are developing, 
and that are winding their way into 
products on store shelves and doc-
tors offices, harbor toxicities and envi-
ronmental hazards that are new. For 
example, could Stupp’s amphiphiles 
end up migrating from the point of 
injection and self-assemble elsewhere 
in ways that, say, interfere with blood 
circulation or the filtering capacity of 
the kidneys?
“We know nanoparticles can pass 
through the blood brain barrier. We 
know they can make it through the 
placenta,” says Toni Marechaux, 
director of the Board on Manufactur-
ing and Engineering Design of the 
National Research Council, a body 
of the National Academy of Sci-
ences. Like many in the nanotech-
nology community, Marechaux and 
her colleagues worry that there may 
be heretofore unrecognized haz-
ards posed by nanotechnologies as 
they enter widespread use, including 
those already on the market, such 
as sunscreens containing nanoscale 
particles of titanium dioxide. The toxi-
cology studies have yet to be done, 
Marechaux notes. “We just don’t 
know what the dangers might be.” 
That’s true for every new nanoscale 
entity under development.
Researchers in academia, indus-
try, and government have only just 
begun to design and undertake health 
and environmental hazard studies for 
nanotechnologies. Early data indicate 
that nanoscale particles can pass 
through the skin and, in the case of 
carbon nanotubes, can lead to inflam-
mation when inhaled into the lung, 
leading to the formation of small scar 
patches called granulomas. Accord-
ing to a National Toxicology Program 
fact sheet on nanoparticles, “particle 
size can impart toxicity equally if not 
more so than chemical composition,” a ember 16, 2005 ©2005 Elsevier Inc. 969
phenomenon “that hints at the com-
plexity of the topic.” What’s more, 
“there are indications…that manufac-
tured nanoscale materials may distrib-
ute in the body in unpredictable ways.”
“I am concerned about what could 
happen,” says Baker, a member of 
the Nanotechnology Technical Advi-
sory Group of the President’s Council 
of Advisors on Science and Technol-970 Cell 123, December 16, 2005 ©2005 Eogy. “I think it’s crazy to have abject 
fear, but we need to be careful. If we 
in the field are claiming that by mak-
ing particles nanoscale, we impart 
something unique to them, then we 
can’t argue at the same time that we 
know they are safe.”
The world is full of dangerous medi-
cines and technologies that are bene-
ficial because their toxicities and other lsevier Inc.hazards are known and manageable 
and their benefits are deemed to out-
weigh their risks, points out Teague, 
director of the National Nanotechnol-
ogy Coordinating Office. With that 
reality long in place, he and other 
biological nanotechnology devotees 
believe that the same ought to hold 
for the nanoscale wonders that they 
are making real.
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